Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Kinnate Biopharma

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
From Kinnate Biopharma
Via GlobeNewswire
Tickers KNTE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.